Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Stakeholder Deadline May Come After Negotiations Conclude

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.


Related Content

FDA Generic Office Director Uhl Returns From Medical Leave
ANDA Approvals: Is FDA Productivity Boost Permanent?
ANDA Sponsors: Update Your FDA Contacts List
GPhA Warns FDA On ANDA Review Transparency
GDUFA Stakeholder Deadline Extended; Are Talks Delayed?
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up
FDASIA Is Signed, Not That White House Wanted Anyone To Notice
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts